Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cost Effectiveness and Resource Allocation
Published in: Cost Effectiveness and Resource Allocation 1/2008

Open Access 01-12-2008 | Research

Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis

Authors: Shalini L Kulasingam, Steve Benard, Ruanne V Barnabas, Nathalie Largeron, Evan R Myers

Published in: Cost Effectiveness and Resource Allocation | Issue 1/2008

Login to get access

Abstract

Background

We assessed the cost-effectiveness of adding a quadrivalent (6/11/16/18) human papillomavirus (HPV) vaccine to the current screening programme in the UK compared to screening alone.

Methods

A Markov model of the natural history of HPV infection incorporating screening and vaccination was developed. A vaccine that prevents 98% of HPV 6, 11, 16 and 18-associated disease, with a lifetime duration and 85% coverage, in conjunction with current screening was considered.

Results

Vaccination with screening, compared to screening alone, was associated with an incremental cost-effectiveness ratio of £21,059 per quality adjusted life year (QALY) and £34,687 per life year saved (LYS). More than 400 cases of cervical cancer, 6700 cases of cervical intraepithelial neoplasia and 4750 cases of genital warts could be avoided per 100,000 vaccinated girls. Results were sensitive to assumptions about the need for a booster, the duration of vaccine efficacy and discount rate.

Conclusion

These analyses suggest that adding a quadrivalent HPV vaccine to current screening in the UK could be a cost-effective method for further reducing the burden of cervical cancer.
Appendix
Available only for authorised users
Literature
1.
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999,189(1):12–19. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-FPubMedCrossRef
2.
(EMEA) EMA: European Public Assessment Report (EPAR) for Gardasil. 2006.
3.
(EMEA) EMA: European Public Assessment Report (EPAR) for Cervarix. 2007.
4.
(National) DH: HPV vaccine recommended for NHS immunisation programme. 2007.
5.
Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005,6(5):271–278. 10.1016/S1470-2045(05)70101-7PubMedCrossRef
6.
Future II: Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007,356(19):1915–1927. 10.1056/NEJMoa061741CrossRef
7.
Health Protection Agency: Diagnoses and Rates of Selected STIs Seen at GUM Clinics, United Kingdom: 2000 - 2004. National, Regional and Strategic Health Authority Summary Tables. 2005.
8.
O'Mahony C: Genital warts: current and future management options. Am J Clin Dermatol 2005,6(4):239–243. 10.2165/00128071-200506040-00004PubMedCrossRef
9.
Maw RD, Reitano M, Roy M: An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. Int J STD AIDS 1998,9(10):571–578. 10.1258/0956462981921143PubMedCrossRef
10.
Greer CE, Wheeler CM, Ladner MB, Beutner K, Coyne MY, Liang H, Langenberg A, Yen TS, Ralston R: Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol 1995,33(8):2058–2063.PubMedCentralPubMed
11.
Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007,356(19):1928–1943. 10.1056/NEJMoa061760PubMedCrossRef
12.
Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB: Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000,151(12):1158–1171.PubMedCrossRef
13.
McCrory DC, Matchar DB, Bastian L: Evaluation of Cervical Cytology. In Evid Rep Technol Assess. Agency for Healthcare Quality and Research; 1999.
14.
Melkert PW, Hopman E, van den Brule AJ, Risse EK, van Diest PJ, Bleker OP, Helmerhorst T, Schipper ME, Meijer CJ, Walboomers JM: Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer 1993,53(6):919–923.PubMedCrossRef
15.
Schiffman M, Kjaer SK: Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003, 14–19.
16.
Office for National Statistics: Cancer statistics registrations: Registrations of cancer diagnosed in 2002, England. Series 2005.,MB1(33):
17.
Canfell K, Barnabas R, Patnick J, Beral V: The predicted effect of changes in cervical screening practice in the UK: results from a modelling study. Br J Cancer 2004,91(3):530–536. 10.1038/sj.bjc.6602002PubMedCentralPubMedCrossRef
18.
Office for National Statistics: Mortality statistics: Review of the Register General on deaths by cause, sex and age, in England and Wales, 2002. 2003 .
19.
Redburn JC, Murphy MF: Hysterectomy prevalence and adjusted cervical and uterine cancer rates in England and Wales. Bjog 2001,108(4):388–395. 10.1016/S0306-5456(00)00098-XPubMed
20.
Bjorge T, Thoresen SO, Skare GB: Incidence, survival and mortality in cervical cancer in Norway, 1956–1990. Eur J Cancer 1993,29A(16):2291–2297. 10.1016/0959-8049(93)90224-4PubMedCrossRef
21.
Cancer Research UK: Cervical cancer survival statistics. 2004 .
22.
NHS Cancer Screening Programmes: NHS Cervical Screening Programme. 2005.
23.
Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, Matchar DB: Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000,132(10):810–819.PubMedCrossRef
24.
Kulasingam SL, Myers ER: Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. Jama 2003,290(6):781–789. 10.1001/jama.290.6.781PubMedCrossRef
25.
Karnon J, Peters J, Platt J, Chilcott J, McGoogan E, Brewer N: Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis. Health Technol Assess 2004,8(20):iii, 1–78.CrossRef
26.
Brown RE, Breugelmans JG, Theodoratou D, Benard S: Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Curr Med Res Opin 2006,22(4):663–670. 10.1185/030079906X99972PubMedCrossRef
27.
Mitchell MF, Schottenfeld D, Tortolero-Luna G, Cantor SB, Richards-Kortum R: Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998,91(4):626–631. 10.1016/S0029-7844(98)00006-4PubMedCrossRef
28.
Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, Iversen OE, Hoye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, von Krogh G, Lehtinen M, Paavonen J, Tamms GM, Giacoletti K, Lupinacci L, Esser MT, Vuocolo SC, Saah AJ, Barr E: Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007,25(26):4931–4939. 10.1016/j.vaccine.2007.03.049PubMedCrossRef
29.
Kohli M, Ferko N, Martin A, Franco EL, Jenkins D, Gallivan S, Sherlaw-Johnson C, Drummond M: Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. Br J Cancer 2007,96(1):143–150. 10.1038/sj.bjc.6603501PubMedCentralPubMedCrossRef
30.
Goldie SJ, Kim JJ, Wright TC: Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol 2004,103(4):619–631.PubMedCrossRef
31.
Trotter CL, Edmunds WJ: Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales. Bmj 2002,324(7341):809. 10.1136/bmj.324.7341.809PubMedCentralPubMedCrossRef
32.
Bramley JC, Wallace LA, Ahmed S: Universal hepatitis B vaccination of UK adolescents: a feasibility and acceptability study. Commun Dis Public Health 2002, 5: 318 – 320.PubMed
33.
Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjose S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJ, Franceschi S: Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005,366(9490):991–998. 10.1016/S0140-6736(05)67069-9PubMedCrossRef
34.
Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM: Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005,14(5):1157–1164. 10.1158/1055-9965.EPI-04-0812PubMedCrossRef
35.
Clifford GM, Smith JS, Aguado T, Franceschi S: Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003,89(1):101–105. 10.1038/sj.bjc.6601024PubMedCentralPubMedCrossRef
36.
Goldie SJ, Grima D, Kohli M, Wright TC, Weinstein M, Franco E: A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 2003,106(6):896–904. 10.1002/ijc.11334PubMedCrossRef
37.
Wolstenholme JL, Whynes DK: Stage-specific treatment costs for cervical cancer in the United Kingdom. Eur J Cancer 1998,34(12):1889–1893. 10.1016/S0959-8049(98)00232-9PubMedCrossRef
38.
Curtis L, Netten A: Unit costs of health and social care 2005. Edited by: PSSRU . University of Kent (United Kingdom) ; 2005.
39.
Myers ER, Green S, Lipkus I: Patient preferences for health states related to HPV infection: visual analogue scales vs time trade-off elicitation. In International HPV Meeting, Mexico City, Mexico. ; 2004.
40.
Insinga RP, Glass AG, Myers ER, Rush BB: Abnormal Outcomes Following Cervical Cancer Screening: Event Duration and Health Utility Loss. Medical Decision Making 2007, 27: 414–422. 10.1177/0272989X07302128PubMedCrossRef
41.
Parkin DM: The epidemiological basis for evaluating screening policies. In New developments in cervical cancer screening and prevention. Oxford (United Kingdom) , Blackwell Science ltd; 1997.
42.
Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Hoye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, Krogh G, Lehtinen M, Malm C, Tamms GM, Giacoletti K, Lupinacci L, Railkar R, Taddeo FJ, Bryan J, Esser MT, Sings HL, Saah AJ, Barr E: High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006,95(11):1459–1466. 10.1038/sj.bjc.6603469PubMedCentralPubMedCrossRef
43.
Dasbach EJ, Elbasha EH, Insinga RP: Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 2006, 28: 88–100. 10.1093/epirev/mxj006PubMedCrossRef
44.
45.
Parkin DM, Bray F: Chapter 2: The burden of HPV-related cancers. Vaccine 2006, 24 Suppl 3: S11–25. 10.1016/j.vaccine.2006.05.111CrossRef
46.
Van de Velde N, Brisson M, Boily MC: Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol 2007,165(7):762–775. 10.1093/aje/kwk059PubMedCrossRef
Metadata
Title
Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis
Authors
Shalini L Kulasingam
Steve Benard
Ruanne V Barnabas
Nathalie Largeron
Evan R Myers
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Cost Effectiveness and Resource Allocation / Issue 1/2008
Electronic ISSN: 1478-7547
DOI
https://doi.org/10.1186/1478-7547-6-4

Other articles of this Issue 1/2008

Cost Effectiveness and Resource Allocation 1/2008 Go to the issue

Research

People's willingness to pay for health insurance in rural Vietnam

Research

Review of Australian health economic evaluation – 245 interventions: what can we say about cost effectiveness?

Research

Formulas for estimating the costs averted by sexually transmitted infection (STI) prevention programs in the United States

Research

Cost-effectiveness analysis for joint pain treatment in patients with osteoarthritis treated at the Instituto Mexicano del Seguro Social (IMSS): Comparison of nonsteroidal anti-inflammatory drugs (NSAIDs) vs. cyclooxygenase-2 selective inhibitors

Research

Dynamic effects of smoking cessation on disease incidence, mortality and quality of life: The role of time since cessation

Research

Does productivity influence priority setting? A case study from the field of CVD prevention